title: Discontinuation of risperidone and reversibility of weight gain in children with disruptive behavior disorders.
abstract: Although atypical antipsychotics generally have a good side effect profile and are clinically very effective, weight gain and associated problems accompany their use. The authors followed up 14 subjects who were in studies of risperidone for management of disruptive behavior disorders. The subjects exited after a mean exposure of 8.9 months because of excessive weight gain, or excessive appetite, or insufficient clinical response. Weight was monitored for the full cohort before risperidone treatment, at termination, and (for various subgroups) at 3, 9-12, and 24 months after termination. Analysis of standardized weight scores in relation to standardized BMI scores suggested marked similarity between them at all time points. Comparison of standardized weights at time of drug termination with 3, 9-12, and 24 months after termination indicated that weight gain during risperidone treatment is reversible (i.e., significantly less weight after risperidone was discontinued) at all time points after termination. Furthermore, standardized weight at 12 and 24 months after discontinuation of risperidone was not distinguishable from standardized weight before risperidone. The prospect of reversibility may provide some comfort for clinicians and parents alike, but far more data are needed before an assumption can be made that this is the case for all children. The authors provide several recommendations for clinicians and researchers working with atypical antipsychotics.
authors.affiliation: The Nisonger Center for Mental Retardation, Ohio State University, Columbus, Ohio, USA.
authors.forename: Ronald L
authors.initials: RL
authors.lastname: Lindsay
authors.forename: Sarah
authors.initials: S
authors.lastname: Leone
authors.forename: Michael G
authors.initials: MG
authors.lastname: Aman
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects*; D002648:Child; D002653:Child Behavior Disorders / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D018967:Risperidone / Q000009:adverse effects*; D015430:Weight Gain / Q000187:drug effects*; D015431:Weight Loss
chemical_list: D014150:Antipsychotic Agents; D018967:Risperidone